Natural history of mphysema

Proceedings of the American Thoracic Society

Volumn 5, Issue 4, 2008, Pages 468-474

  Minai, Omar A ^a   Benditt, Joshua ^b   Martinez, Fernando J ^c,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Emphysema; Natural history; Pulmonary function; Quality of life; Survival

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DISEASE SEVERITY; EMPHYSEMA; EXERCISE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HISTORY; HUMAN; LUNG FUNCTION; MORTALITY; PREDICTOR VARIABLE; PREVALENCE; REVIEW; RISK FACTOR; SPIROMETRY; SYMPTOM; AGE; HEALTH SURVEY; HOSPITALIZATION; LUNG EMPHYSEMA; LUNG FUNCTION TEST; PATHOPHYSIOLOGY; QUALITY OF LIFE; SEX DIFFERENCE;

AGE FACTORS; DISEASE PROGRESSION; HEALTH STATUS INDICATORS; HUMANS; PREVALENCE; PULMONARY EMPHYSEMA; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 43449135339     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200802-018ET     Document Type: Review

References (95)

1. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946.
2. World Health Organization. The GOLD global strategy for the management and prevention of COPD: Executive summary 2006 [Accessed 2007 Jul 21]. Available from: http://www.goldcopd.org.
3. Celli BR, Halbert RJ, Isonaka S, Schau B. Population impact of different definitions of airway obstruction. Eur Respir J 2003;22:268-273.
4. Kohler D, Fischer J, Raschke F, Schonhofer B. Usefulness of GOLD classification of COPD severity. Thorax 2003;58:825.
5. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77-S121.
6. Higgins MW, Thom T. Incidence, prevalence, and mortality: intra and inter-country differences. In: Hensley MJ, Saunders NA, editors. Clinical epidemiology of chronic obstructive pulmonary disease. New York: Marcel Dekker Inc.; 1989. pp. 23-42.
7. Bang KM. Prevalence of chronic obstructive pulmonary disease in blacks. J Natl Med Assoc 1993;85:51-55.
8. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006;28:523-532.
9. Viegi G, Pedreschi M, Pistelli F, Di Pede F, Baldacci S, Carrozzi L, Giuntini C. Prevalence of airways obstruction in a general population: European Respiratory Society vs. American Thoracic Society definition. Chest 2000;117:S339-S345.
10. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983;127:725-734.
11. van Pelt W, Borsboom GJJM, Rijcken B, Schouten JP, van Zomeren BC, Quanjer PH. Discrepancies between longitudinal and cross-sectional change in ventilatory function in 12 years of follow-up. Am J Respir Crit Care Med 1994;149:1218-1226.
12. Morris JF, Koski A, Johnson LC. Spirometric standards for healthy nonsmoking adults. Am Rev Respir Dis 1971;103:57-67.
13. Burrows B, Lebowitz MD, Camilli AE, Knudson RJ. Longitudinal changes in forced expiratory volume in one second in adults. Methodologic considerations and findings in healthy nonsmokers. Am Rev Respir Dis 1986;133:974-980.
14. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981;123:659-664.
15. Brandli O, Schindler C, Kunzli N, Keller R, Perruchoud AP. Sapaldia team. Lung function in healthy never smoking adults: reference values and lower limits of normal of a Swiss population. Thorax 1996;51:277-283.
16. Fletcher CM, Peto R, Tinker CM, Speizer FE. The natural history of chronic bronchitis and emphysema. An eight-year study of early chronic obstructive lung disease in working men in London. Oxford: Oxford University Press, 1976.
17. Glindmeyer HW, Lefante JJ, McColloster C, Jones RN, Weill H. Bluecollar normative spirometric values for Caucasian and African American men and women aged 18 to 65. Am J Respir Crit Care Med 1995;151:412-422.
18. Ware JH, Dockery DW, Louis TA, Xu XP, Ferris BG Jr, Speizer FE. Longitudinal and cross-sectional estimates of pulmonary function decline in never-smoking adults. Am J Epidemiol 1990;132:685-700.
19. Tager IB, Ngo L, Hanrahan JP. Maternal smoking during pregnancy: effects on lung function during the first 18 months of life. Am J Respir Crit Care Med 1995;152:977-983.
20. Young S, Le Souef PN, Geelhoed GC, Stick SM, Turner KJ, Landau LI. The influence of a family history of asthma and paternal smoking on airway responsiveness in early infancy. N Engl J Med 1991;324:1168-1173.
21. Wang X, Wypij D, Gold DR, Speizer FE, Ware JH, Ferris BG Jr, Dockery DW. A longitudinal study of the effects of parental smoking on pulmonary function in children 6-18 years. Am J Respir Crit Care Med 1994;149:1420-1425.
22. Tager IB, Weiss ST, Munoz A, Rosner B, Speizer FE. Longitudinal study of the effects of maternal smoking on pulmonary function in children. N Engl J Med 1983;309:699-703.
23. Cook DG, Strachan DP, Carey IM. Health effects of passive smoking. 9. Parental smoking and spirometric indices in children. Thorax 1998;53:884-893.
24. Cook DG, Strachan DP. Summary of effects of parental smoking on the respiratory health of children and implications for research. Thorax 1999;54:357-366.
25. Gold DR, Wang X, Wypij D, Speizer FE, Ware JH, Dockery DW. Effects of cigarette smoking on lung function in adolescent boys and girls. N Engl J Med 1996;335:931-937.
26. Lebowitz MD, Holberg CJ, Knudson RJ, Burrows B. Longitudinal study of pulmonary function development in childhood, adolescence, and early adulthood: development of pulmonary function. Am Rev Respir Dis 1987;136:69-75.
27. Tager IB, Munoz A, Rosner B, Weiss S, Carey V. Effect of cigarette smoking on the pulmonary function of children and adolescents. Am Rev Respir Dis 1985;131:752-759.
28. Tager IB, Segal MR, Speizer FE, Weiss ST. The natural history of forced expiratory volumes: effect of cigarette smoking and respiratory symptoms. Am Rev Respir Dis 1988;138:837-849.
29. Samet JM, Lange P. Longitudinal studies of active and passive smoking. Am J Respir Crit Care Med 1996;154:S257-S265.
30. Sherrill DL, Lebowitz MD, Knudson RJ, Burrows B. Smoking and symptom effects on the curves of lung function growth and decline. Am Rev Respir Dis 1991;144:17-22.
31. Dockery DW, Ware JH, Ferris BG Jr, Glicksberg DS, Fay ME, Spiro A 3rd, Speizer FE. Distribution of forced expiratory volume in one second and forced vital capacity in healthy, white, adult never-smokers in six US cities. Am Rev Respir Dis 1985;131:511-520.
32. Kerstjens HAM, Rijcken B, Schouten JP, Postma DS. Decline of FEV1 by age and smoking status: facts, figures, and fallacies. Thorax 1997;52:820-827.
33. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA Jr, Enright PL, Kanner RE, O'Hara P, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA 1994;272:1497-1505.
34. Gottlieb DJ, Stone PJ, Sparrow D, Gale ME, Weiss ST, Snider GL, O'Connor GT. Urinary desmosine excretion in smokers with and without rapid decline of lung function. Am J Respir Crit Care Med 1996;154:1290-1295.
35. Han MK, Postma D, Mannino D, Giardino ND, Buist S, Curtis JL, Martinez FJ. Gender and COPD: why it matters. Am J Respir Crit Care Med 2007;176:1179-1184.
36. Xu S, Weiss ST, Rijcken B, Schouten JP. Smoking, changes in smoking habits, and rate of decline in FEV1: new insight into gender differences. Eur Respir J 1994;7:1056-1106.
37. Burchfiel CM, Marcus EB, Curb JD, MacLean CJ, Vollmer WM, Johnson LR, Fong KO, Rodriguez BL, Masaki KH, Buist AS. Effects of smoking and smoking cessation on longitudinal decline in pulmonary function. Am J Respir Crit Care Med 1995;151:1778-1785.
38. Lange P, Groth S, Nyboe J, Mortensen J, Appleyard M, Jensen G, Schnohr P. Effects of smoking and changes in smoking habits on the decline of FEV1. Eur Respir J 1989;2:811-816.
39. Lange P, Groth S, Nyboe J, Mortensen J, Appleyard M, Jensen G, Schnohr P. Decline of the lung function related to the type of tobacco smoked and inhalation. Thorax 1990;45:22-26.
40. Camilli AE, Burrows B, Knudson RJ, Lyle SK, Lebowitz MD. Longitudinal changes in forced expiratory volume in one second in adults. (Effects of smoking and smoking cessation). Am Rev Respir Dis 1987;135:794-799.
41. Xu X, Li B, Wang L. Gender differences in smoking effects on adult pulmonary function. Eur Respir J 1994;7:477-483.
42. Silverman E. Gender-related differences in severe, early-onset COPD. Am J Respir Crit Care Med 2000;162:2152-2158.
43. Prescott E, Bjerg AM, Andersen PK, Lange P, Vestbo J. Gender difference in smoking effects on lung function and risk for hospitalization for COPD: results from a Danish longitudinal population study. Eur Respir J 1997;10:822-827.
44. Paoletti P, Carrozzi L, Viegi G, Modena P, Ballerin L, Di Pede F, Grado L, Baldacci S, Pedreschi M, Vellutini M, et al. Distribution of bronchial responsiveness in a general population: effect of sex, age, smoking, and level of pulmonary function. Am J Respir Crit Care Med 1995;151:1770-1777.
45. Smith CA, Harrison DJ. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 1997;350:630-633.
46. Silverman EK, Palmer LJ, Mosley JD, Barth M, Senter JM, Brown A, Drazen JM, Kwiatkowski DJ, Chapman HA, Campbell EJ, et al. Genome wide linkage analysis of quantitative spirometric phenotypes in severe early-onset chronic obstructive pulmonary disease. Am J Hum Genet 2002;70:1229-1239.
47. Anto JM, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001;17:982-994.
48. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood DE, for the National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volumereduction surgery with medical therapy for severe emphysema. N Engl J Med 2003;348:2059-2073.
49. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-1613.
50. Makris D, Moschandreas J, Damianaki A, Ntaoukakis E, Siafakas NM, Milic Emili J, Tzanakis N. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. Respir Med 2007;101:1305-1312.
51. Kanner RE, Anthonisen NR, Connett JE; Lung Health Study Research Group. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the Lung Health Study. Am J Respir Crit Care Med 2001;164:358-364.
52. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-852.
53. Ramsey SD, Berry K, Etzioni R, Kaplan RM, Sullivan SD, Wood DE; National Emphysema Treatment Trial Research Group. Cost effectiveness of lung volume reduction surgery for patients with severe emphysema. N Engl J Med 2003;348:2092-2102.
54. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. Exercise capacity deterioration in patients with COPD: longitudinal evaluation over 5 years. Chest 2005;128:62-69.
55. Casanova C, Cote CG, Marin JM, de Torres JP, Aguirre-Jaime A, Mendez R, Dordelly L, Celli BR. The 6-minute walk distance: long-term follow-up in patients with COPD. Eur Respir J 2007;29:535-540.
56. Sciurba F, Criner GJ, Lee SM, Mohsenifar Z, Shade D, Slivka W, Wise RA; National Emphysema Treatment Trial Research Group. Six-minute walk distance in chronic obstructive pulmonary disease: reproducibility and effect of walking course layout and length. Am J Respir Crit Care Med 2003;167:1522-1527.
57. Naunheim KS, Wood DE, Mosenifar Z, Sternberg AL, Criner GJ, DeCamp MM, Deschamps CC, Martinez FJ, Sciurba FC, Tonascia J, et al. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg 2006;82:431-443.
58. Barr RG, Celli BR, Martinez FJ, Ries AL, Rennard SI, Reilly JJ Jr, Sciurba FC, Thomashow BM, Wise RA. Physician and patient perceptions in COPD: the COPD resource network needs assessment survey. Am J Med 2005;118:1415.
59. Wolkove N, Dajczman E, Colacone A, Kreisman H. The relationship between pulmonary function and dyspnea in obstructive lung disease. Chest 1989;96:1247-1251.
60. Martinez FJ, Curtis JL, Sciurba F, Mumford J, Giardino ND, Weinmann G, Kazerooni E, Murray S, Criner GJ, Sin DD, et al.; National Emphysema Treatment Trial Research Group. Sex differences in severe pulmonary emphysema. Am J Respir Crit Care Med 2007;176:243-252.
61. Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. Chest 1998;113:619-624.
62. Clement J, van de Woestjne KP. Rapidly decreasing forced expiratory volume in one second or vital capacity and development of chronic airway obstruction. Am Rev Respir Dis 1982;125:553-558.
63. Higgins MW, Keller JB, Becker M, Howatt W, Landis JR, Rotman H, Weg JG, Higgins I. An index of risk for obstructive airways disease. Am Rev Respir Dis 1982;125:144-151.
64. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effects of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-1422.
65. Foreman MG, Demeo DL, Hersh CP, Reilly JJ, Silverman EK. Clinical determinants of exacerbations in severe, early-onset COPD. Eur Respir J 2007;22. (Epub ahead of print).
66. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996;153:1530-1535.
67. Heijdra YF, Pinto-Plata VM, Kenney LA, Rassulo J, Celli BR. Cough and phlegm are important predictors of health status in smokers without COPD. Chest 2002;121:1427-1433.
68. Ekberg-Aronsson M, Pehrsson K, Nilsson JA, Nilsson PM, Lofdahl CJ. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res 2005;6:98.
69. Fujimoto K, Kitaguchi Y, Kubo K, Honda T. Clinical analysis of chronic obstructive pulmonary disease phenotypes classified using high-resolution computed tomography. Respirology 2006;11:731-740.
70. de Marco R, Accordini S, Cerveri I, Corsico A, Anto JM, Kunzli N, Janson C, Sunyer J, Jarvis D, Chinn S, et al. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med 2007;175:32-39.
71. Jones P, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation: The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145:1321-1327.
72. Gonzales E, Herrejon A, Incahurraga I, Blanquer R. Determinants of health-related quality of life in patients with pulmonary emphysema. Respir Med 2005;99:638-644.
73. Kaplan RM, Ries AL, Reilly J, Mohsenifar Z. Measurement of health-related quality of life in the national emphysema treatment trial. Chest 2004;126:781-789.
74. Spencer S, Calverly PMA, Burge PS. Jones PW on behalf of the ISOLDE study group. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:122-128.
75. Niewoehner DE. The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease. Am J Med 2006;119:38-45.
76. Stolk J, Ng WH, Bakker ME, Reiber JH, Rabe KF, Putter H, Stoel BC. Correlation between annual change in health status and computer-tomography derived lung density in subjects with alpha 1-antitrypsin deficiency. Thorax 2003;58:1027-1030.
77. Stolk J, Putter H, Bakker EM, Shaker SB, Parr DG, Piitulainen E, Russi EW, Grebski E, Dirksen A, Stockley RA, et al. Progression parameters for emphysema: a clinical investigation. Respir Med 2007;101:1924-1930.
78. Gietema HA, Schilham AM, van Ginneken B, van Klaveren RJ, Lammers JW, Prokop M. Monitoring of smoking-induced emphysema with CT in a lung cancer screening setting: detection of real increase in extent of emphysema. Radiology 2007;244:890-897.
79. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005;294:1255-1259.
80. Martinez FJ, Kotloff R. Prognostication in chronic obstructive pulmonary disease: implications for lung transplantation. Semin Respir Crit Care Med 2001;22:489-498.
81. Cote CG. Surrogates of mortality in chronic obstructive pulmonary disease. Am J Med 2006;119:54-62.
82. Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Clin Chest Med 1990;11:555-569.
83. Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986;133:14-20.
84. Anthonisen NR. Prognosis in chronic obstructive pulmonary disease: results from multi-center clinical trials. Am Rev Respir Dis 1989;140:S95-S99.
85. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-minute walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 2004;23:28-33.
86. Fisher MR, Criner GJ, Fishman AP, Hassoun P, Minai OA, Scharf SM, Fessler AH, et al. for the National Emphysema Treatment trial Research Group. Estimating pulmonary artery pressures by echocardiography in patients with emphysema. Eur Respir J 2007;30:914-921.
87. Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE, for the National Emphysema Treatment trial Research Group. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 2002;166:314-322.
88. Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, Charpentier C, Kessler R. Prognostic factors in COPD patients receiving long-term oxygen therapy: importance of pulmonary artery pressure. Chest 1995;107:1193-1198.
89. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-1012.
90. Burrows B, Bloom JW, Traver GA, Cline MG. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med 1987;317:1309-1314.
91. Brantly ML, Paul LD, Miller BH, Falk RT, Wu M, Crystal RG. Clinical features and history of the destructive lung disease associated with alpha 1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis 1988;138:327-336.
92. Seersholm N, Dirksen A, Kok-Jensen A. Airways obstruction and two year survival in patients with severe alpha 1-antitrypsin deficiency. Eur Respir J 1994;7:1985-1987.
93. Stoller JK, Aboussouan LS. Alpha-1 antitrypsin deficiency. Lancet 2005;365:2225-2236.
94. Martinez FJ, Foster G, Curtis JL, Criner G, Weinmann G, Fishman A, DeCamp MM, Benditt J, Sciurba F, Make B, et al.; NETT Research Group. Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med 2006;173:1326-1334.
95. Hogg JC, Chu FS, Tan WC, Sin DD, Patel SA, Pare PD, Martinez FJ, Rogers RM, Make BJ, Criner GJ, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med 2007;176:454-459.